Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study

Duygu Tosun, Norbert Schuff, Diana Truran-Sacrey, Leslie M. Shaw, John Q. Trojanowski, Paul Aisen, Ronald Carl Petersen, Michael W. Weiner

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Previously it was reported that Alzheimer's disease (AD) patients have reduced beta amyloid (Aβ1-42) and elevated total tau (t-tau) and phosphorylated tau (p-tau181p) in the cerebrospinal fluid (CSF), suggesting that these same measures could be used to detect early AD pathology in healthy elderly individuals and those with mild cognitive impairment (MCI). In this study, we tested the hypothesis that there would be an association among rates of regional brain atrophy, the CSF biomarkers Aβ1-42, t-tau, and p-tau181p and apolipoprotein E (ApoE) ε4 status, and that the pattern of this association would be diagnosis-specific. Our findings primarily showed that lower CSF Aβ1-42 and higher tau concentrations were associated with increased rates of regional brain tissue loss and the patterns varied across the clinical groups. Taken together, these findings demonstrate that CSF biomarker concentrations are associated with the characteristic patterns of structural brain changes in healthy elderly and mild cognitive impairment subjects that resemble to a large extent the pathology seen in AD. Therefore, the finding of faster progression of brain atrophy in the presence of lower Aβ1-42 levels and higher tau levels supports the hypothesis that CSF Aβ1-42 and tau are measures of early AD pathology. Moreover, the relationship among CSF biomarkers, ApoE ε4 status, and brain atrophy rates are regionally varying, supporting the view that the genetic predisposition of the brain to beta amyloid and tau mediated pathology is regional and disease stage specific.

Original languageEnglish (US)
Pages (from-to)1340-1354
Number of pages15
JournalNeurobiology of Aging
Volume31
Issue number8
DOIs
StatePublished - Aug 1 2010

Fingerprint

Apolipoproteins E
Longitudinal Studies
Cerebrospinal Fluid
Biomarkers
Alzheimer Disease
Brain
Pathology
Apolipoprotein E4
Atrophy
Amyloid
Genetic Predisposition to Disease

Keywords

  • Alzheimer's disease
  • ApoE
  • Atrophy
  • Biomarkers
  • Brain tissue volume
  • Cerebrospinal fluid
  • Cortical thickness
  • Healthy aging
  • Mild cognitive impairment
  • MRI

ASJC Scopus subject areas

  • Neuroscience(all)
  • Aging
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Tosun, D., Schuff, N., Truran-Sacrey, D., Shaw, L. M., Trojanowski, J. Q., Aisen, P., ... Weiner, M. W. (2010). Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study. Neurobiology of Aging, 31(8), 1340-1354. https://doi.org/10.1016/j.neurobiolaging.2010.04.030

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile : A longitudinal MRI study. / Tosun, Duygu; Schuff, Norbert; Truran-Sacrey, Diana; Shaw, Leslie M.; Trojanowski, John Q.; Aisen, Paul; Petersen, Ronald Carl; Weiner, Michael W.

In: Neurobiology of Aging, Vol. 31, No. 8, 01.08.2010, p. 1340-1354.

Research output: Contribution to journalArticle

Tosun, D, Schuff, N, Truran-Sacrey, D, Shaw, LM, Trojanowski, JQ, Aisen, P, Petersen, RC & Weiner, MW 2010, 'Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study', Neurobiology of Aging, vol. 31, no. 8, pp. 1340-1354. https://doi.org/10.1016/j.neurobiolaging.2010.04.030
Tosun, Duygu ; Schuff, Norbert ; Truran-Sacrey, Diana ; Shaw, Leslie M. ; Trojanowski, John Q. ; Aisen, Paul ; Petersen, Ronald Carl ; Weiner, Michael W. / Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile : A longitudinal MRI study. In: Neurobiology of Aging. 2010 ; Vol. 31, No. 8. pp. 1340-1354.
@article{306afdb8d5bb4669b1dd3f03bcca26b4,
title = "Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study",
abstract = "Previously it was reported that Alzheimer's disease (AD) patients have reduced beta amyloid (Aβ1-42) and elevated total tau (t-tau) and phosphorylated tau (p-tau181p) in the cerebrospinal fluid (CSF), suggesting that these same measures could be used to detect early AD pathology in healthy elderly individuals and those with mild cognitive impairment (MCI). In this study, we tested the hypothesis that there would be an association among rates of regional brain atrophy, the CSF biomarkers Aβ1-42, t-tau, and p-tau181p and apolipoprotein E (ApoE) ε4 status, and that the pattern of this association would be diagnosis-specific. Our findings primarily showed that lower CSF Aβ1-42 and higher tau concentrations were associated with increased rates of regional brain tissue loss and the patterns varied across the clinical groups. Taken together, these findings demonstrate that CSF biomarker concentrations are associated with the characteristic patterns of structural brain changes in healthy elderly and mild cognitive impairment subjects that resemble to a large extent the pathology seen in AD. Therefore, the finding of faster progression of brain atrophy in the presence of lower Aβ1-42 levels and higher tau levels supports the hypothesis that CSF Aβ1-42 and tau are measures of early AD pathology. Moreover, the relationship among CSF biomarkers, ApoE ε4 status, and brain atrophy rates are regionally varying, supporting the view that the genetic predisposition of the brain to beta amyloid and tau mediated pathology is regional and disease stage specific.",
keywords = "Alzheimer's disease, ApoE, Atrophy, Biomarkers, Brain tissue volume, Cerebrospinal fluid, Cortical thickness, Healthy aging, Mild cognitive impairment, MRI",
author = "Duygu Tosun and Norbert Schuff and Diana Truran-Sacrey and Shaw, {Leslie M.} and Trojanowski, {John Q.} and Paul Aisen and Petersen, {Ronald Carl} and Weiner, {Michael W.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1016/j.neurobiolaging.2010.04.030",
language = "English (US)",
volume = "31",
pages = "1340--1354",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile

T2 - A longitudinal MRI study

AU - Tosun, Duygu

AU - Schuff, Norbert

AU - Truran-Sacrey, Diana

AU - Shaw, Leslie M.

AU - Trojanowski, John Q.

AU - Aisen, Paul

AU - Petersen, Ronald Carl

AU - Weiner, Michael W.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Previously it was reported that Alzheimer's disease (AD) patients have reduced beta amyloid (Aβ1-42) and elevated total tau (t-tau) and phosphorylated tau (p-tau181p) in the cerebrospinal fluid (CSF), suggesting that these same measures could be used to detect early AD pathology in healthy elderly individuals and those with mild cognitive impairment (MCI). In this study, we tested the hypothesis that there would be an association among rates of regional brain atrophy, the CSF biomarkers Aβ1-42, t-tau, and p-tau181p and apolipoprotein E (ApoE) ε4 status, and that the pattern of this association would be diagnosis-specific. Our findings primarily showed that lower CSF Aβ1-42 and higher tau concentrations were associated with increased rates of regional brain tissue loss and the patterns varied across the clinical groups. Taken together, these findings demonstrate that CSF biomarker concentrations are associated with the characteristic patterns of structural brain changes in healthy elderly and mild cognitive impairment subjects that resemble to a large extent the pathology seen in AD. Therefore, the finding of faster progression of brain atrophy in the presence of lower Aβ1-42 levels and higher tau levels supports the hypothesis that CSF Aβ1-42 and tau are measures of early AD pathology. Moreover, the relationship among CSF biomarkers, ApoE ε4 status, and brain atrophy rates are regionally varying, supporting the view that the genetic predisposition of the brain to beta amyloid and tau mediated pathology is regional and disease stage specific.

AB - Previously it was reported that Alzheimer's disease (AD) patients have reduced beta amyloid (Aβ1-42) and elevated total tau (t-tau) and phosphorylated tau (p-tau181p) in the cerebrospinal fluid (CSF), suggesting that these same measures could be used to detect early AD pathology in healthy elderly individuals and those with mild cognitive impairment (MCI). In this study, we tested the hypothesis that there would be an association among rates of regional brain atrophy, the CSF biomarkers Aβ1-42, t-tau, and p-tau181p and apolipoprotein E (ApoE) ε4 status, and that the pattern of this association would be diagnosis-specific. Our findings primarily showed that lower CSF Aβ1-42 and higher tau concentrations were associated with increased rates of regional brain tissue loss and the patterns varied across the clinical groups. Taken together, these findings demonstrate that CSF biomarker concentrations are associated with the characteristic patterns of structural brain changes in healthy elderly and mild cognitive impairment subjects that resemble to a large extent the pathology seen in AD. Therefore, the finding of faster progression of brain atrophy in the presence of lower Aβ1-42 levels and higher tau levels supports the hypothesis that CSF Aβ1-42 and tau are measures of early AD pathology. Moreover, the relationship among CSF biomarkers, ApoE ε4 status, and brain atrophy rates are regionally varying, supporting the view that the genetic predisposition of the brain to beta amyloid and tau mediated pathology is regional and disease stage specific.

KW - Alzheimer's disease

KW - ApoE

KW - Atrophy

KW - Biomarkers

KW - Brain tissue volume

KW - Cerebrospinal fluid

KW - Cortical thickness

KW - Healthy aging

KW - Mild cognitive impairment

KW - MRI

UR - http://www.scopus.com/inward/record.url?scp=77954030909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954030909&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2010.04.030

DO - 10.1016/j.neurobiolaging.2010.04.030

M3 - Article

C2 - 20570401

AN - SCOPUS:77954030909

VL - 31

SP - 1340

EP - 1354

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 8

ER -